111 (NASDAQ:YI) Earns Sell (E+) Rating from Weiss Ratings

111 (NASDAQ:YI)‘s stock had its “sell (e+)” rating reiterated by investment analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

111 Stock Up 0.4 %

Shares of YI opened at $8.02 on Wednesday. The firm has a 50-day moving average price of $6.39 and a 200 day moving average price of $7.42. The firm has a market capitalization of $68.57 million, a PE ratio of -2.01 and a beta of 0.41. 111 has a 52-week low of $4.14 and a 52-week high of $15.80.

111 (NASDAQ:YI) last issued its quarterly earnings results on Wednesday, November 27th. The company reported ($0.20) earnings per share for the quarter.

Institutional Investors Weigh In On 111

Institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its stake in 111 by 43,619.9% during the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock valued at $191,000 after buying an additional 305,339 shares in the last quarter. FIL Ltd purchased a new stake in 111 during the fourth quarter valued at about $450,000. Finally, Napean Trading & Investment Co Singapore PTE Ltd purchased a new stake in 111 during the fourth quarter valued at about $245,000. 21.32% of the stock is owned by institutional investors and hedge funds.

About 111

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.